Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

Feng Wang

Senior Scientist

Feng Wang is a Senior Scientist leading research and development projects at Inspirna. He received his M.D. from the Norman Bethune College of Medicine at Jilin University in China, and his Ph.D. from the Graduate School of Medicine at the University of Tokyo. Following a postdoctoral research fellowship at Memorial Sloan Kettering Cancer Center, Feng joined the Alberta Einstein College of Medicine, where he led multiple translational studies that characterized novel oncogenic drivers in lung tumor growth, metastasis, and immuno-oncology, and developed innovative therapeutics for cancer treatment. Feng’s research discoveries have been published in leading journals, including Cancer Research, Science Translational Medicine, the Proceedings of the National Academy of Sciences (PNAS), and the Journal of Biological Chemistry.